Uppsala Forum 2020: Putting pharmacovigilance on trial

At the 2020 edition of Uppsala Monitoring Centre’s cutting-edge research conference, we’ll be making the case for evidence of impact.

In 2018, we celebrated the 50th birthday of the WHO Programme for International Drug Monitoring and the 40th of Uppsala Monitoring Centre. Many people have worked very hard over all these years and we see progress: the programme now counts more than 130 contributing countries and over 20 million reports are available in VigiBase, the global database for individual case safety reports. Many safety issues have been identified and risk minimisation measures taken, and regulatory systems are being strengthened all over the world.

The scope of pharmacovigilance has expanded to also include medication errors, substandard and falsified medicines, medical devices and rational use of medicines. Moreover, many more stakeholders are reporting unwanted effects of treatments, thus sharing different perspectives and perceptions on safety.

But are we making an impact? Are we achieving our vision of a wiser use of medicines and safer patients? And how do we know whether we are on the right track? These are questions we will discuss at Uppsala Forum: Putting pharmacovigilance on trial, on 28-29 May 2020.

Invitations were sent out during the latter part of 2019. More information will follow.

Past research conferences

2018: UMC 40th Anniversary Conference

In 2018, Uppsala Forum was replaced by UMC’s 40th Anniversary conference, where key actors from the past and present of the WHO Programme for International Drug Monitoring joined pharmacovigilance colleagues to reflect on the progress pharmacovigilance has made since the programme’s inception in 1968.

Rapid Fire talks Uppsala Reports coverage

Uppsala Forum 2016: Pharmacovigilance’s role in rapid access to safer drugs

The need to develop and rapidly deploy new treatments tests the limits of traditional pharmacovigilance and demands new thinking and practice. How can we ensure the safety of patients using new drugs when rapid access is of paramount importance?

Rapid Fire talks 2016 Conference Report

Uppsala Forum 2014: Risk: What risk? Whose risk?

Topics covered included: Patient groups at risk – genotypes and phenotypes; Structure analysis of medicinal products; Detection and confirmation of signals; Individualised benefit-risk assessment; Effective communication to health professionals and patients in clinical settings.

Uppsala Forum 2012: Causality assessment in an evolving pharmacovigilance landscape

Causality assessment plays a critical part in the search for better science and safer use of medicines. Although the principles of causality assessment are straightforward, the application of those principles to an individual case is a philosophical as well as a scientific challenge.

Uppsala Forum Conference Report 2012

Last modified on: January 16, 2020